Home › All Companies › ZBIO › Current Report

Zenas BioPharma, Inc. (ZBIO) — Current Report

AI-Powered SEC Filing Analysis

← All ZBIO filings
Latest Current Report Filed: 2026-02-13

Key Insights

  • Zenas BioPharma, Inc. has implemented a new short-term incentive (STI) plan for its employees, effective January 1, 2026, which allows them to earn annual discretionary cash bonuses based on company performance and individual goal achievement.
  • The STI Plan is administered by the Board of Directors for company executives and by the CEO and executive leadership team for other eligible employees, giving the leadership team flexibility in determining bonus payouts.
  • The STI Plan includes provisions for clawback and recoupment of incentive compensation, aligning employee incentives with shareholder interests.
Sentiment: Positive Significance: 6/10
View Original Filing →

Want the newest filings?

This analysis covers the filing from 2026-02-13. New 10-K, 10-Q and 8-K filings are analyzed the moment they are released — exclusively in the app.

Download on the App Store Open in app →

Other reports for Zenas BioPharma, Inc.

Insider Trading

Important Information

AI-generated analysis is for informational purposes only. Always read original SEC filings and consult with qualified professionals before making investment decisions.